Meilleure Health International Industry Group Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Meilleure Health International Industry Group.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Trade Distributors crescita degli utili	6.9%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

Oct 04

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Sep 05

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

Aug 30

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Jul 19

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Jun 17

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

May 03

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Apr 04

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Feb 28

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Jan 23

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Aug 17

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Oct 18

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

Sep 06

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Jul 12

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

Sep 09

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

May 15

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Apr 18

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

Jan 29

Here's What We Think About Meilleure Health International Industry Group's (HKG:2327) CEO Pay

Dec 08

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Meilleure Health International Industry Group non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:2327 - Stime future degli analisti e dati finanziari passati (HKD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	84	31	56	56	N/A
3/31/2024	107	36	-41	-40	N/A
12/31/2023	129	41	-137	-136	N/A
9/30/2023	130	33	-123	-122	N/A
6/30/2023	130	25	-109	-108	N/A
3/31/2023	125	22	-33	-32	N/A
12/31/2022	120	18	42	43	N/A
9/30/2022	148	23	42	46	N/A
6/30/2022	177	28	43	49	N/A
3/31/2022	215	44	-24	-17	N/A
12/31/2021	253	60	-90	-83	N/A
9/30/2021	263	72	-27	-24	N/A
6/30/2021	273	84	35	36	N/A
3/31/2021	269	84	53	53	N/A
12/31/2020	265	83	70	71	N/A
9/30/2020	262	32	11	11	N/A
6/30/2020	259	-19	-49	-48	N/A
3/31/2020	247	-19	-12	-12	N/A
12/31/2019	235	-20	25	25	N/A
9/30/2019	221	31	74	74	N/A
6/30/2019	208	83	123	123	N/A
3/31/2019	219	82	70	70	N/A
12/31/2018	231	81	18	18	N/A
9/30/2018	181	81	-40	-38	N/A
6/30/2018	132	81	-98	-94	N/A
3/31/2018	101	81	N/A	-79	N/A
12/31/2017	69	80	N/A	-63	N/A
9/30/2017	83	60	N/A	-177	N/A
6/30/2017	97	40	N/A	-291	N/A
3/31/2017	82	37	N/A	-276	N/A
12/31/2016	67	34	N/A	-261	N/A
12/31/2015	76	10	N/A	0	N/A
9/30/2015	17	-1	N/A	-45	N/A
6/30/2015	13	0	N/A	-21	N/A
3/31/2015	9	2	N/A	3	N/A
12/31/2014	16	1	N/A	29	N/A
9/30/2014	22	0	N/A	54	N/A
6/30/2014	29	44	N/A	63	N/A
3/31/2014	35	89	N/A	72	N/A
12/31/2013	34	87	N/A	47	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 2327 è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 2327 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 2327 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di 2327 cresceranno più rapidamente del mercato Hong Kong.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di 2327 cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 2327 è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/22 09:35
Prezzo dell'azione a fine giornata	2024/12/20 00:00
Guadagni	2024/06/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Meilleure Health International Industry Group Limited è coperta da 1 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Li Wu	Tianfeng Securities Brokerage Co., Ltd

Meilleure Health International Industry Group Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Recent updates

Executive Co-Chairman of the Board recently bought HK$541k worth of stock

Executive Co-Chairman of the Board recently bought HK$1.2m worth of stock

Executive Co-Chairman of the Board recently bought HK$245k worth of stock

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

First half 2024 earnings released: EPS: HK$0.002 (vs HK$0.004 in 1H 2023)

Now 21% undervalued

Executive Co-Chairman of the Board recently bought HK$432k worth of stock

New major risk - Revenue and earnings growth

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Executive Co-Chairman of the Board recently bought HK$715k worth of stock

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

New minor risk - Share price stability

Meilleure Health International Industry Group Limited to Report First Half, 2024 Results on Aug 31, 2024

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Executive Co-Chairman of the Board recently bought HK$592k worth of stock

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Executive Co-Chairman of the Board recently bought HK$485k worth of stock

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

Executive Co-Chairman of the Board recently bought HK$119k worth of stock

Meilleure Health International Industry Group Limited Announces Board and Committees Changes

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: HK$0.01 (vs HK$0.004 in FY 2022)

Dividend reduced to HK$0.004

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 27, 2024

Meilleure Health International Industry Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 20 August 2024

Meilleure Health International Industry Group Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Now 31% undervalued after recent price drop

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Executive Co-Chairman of the Board recently bought HK$135k worth of stock

Executive Co-Chairman of the Board recently bought HK$133k worth of stock

Executive Co-Chairman of the Board recently bought HK$251k worth of stock

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.003 in 1H 2022)

New minor risk - Earnings quality

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Meilleure Health International Industry Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Upcoming dividend of HK$0.016 per share at 5.4% yield

Executive Co-Chairman of the Board recently bought HK$274k worth of stock

Meilleure Health International Industry Group Limited Approves Final Dividend

Executive Co-Chairman of the Board recently bought HK$153k worth of stock

Executive Co-Chairman of the Board recently bought HK$145k worth of stock

Full year 2022 earnings released: EPS: HK$0.004 (vs HK$0.014 in FY 2021)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Executive Co-Chairman of the Board recently bought HK$272k worth of stock

Executive Co-Chairman of the Board recently bought HK$325k worth of stock

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$169k worth of stock

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.003 (vs HK$0.01 in 1H 2021)

Meilleure Health International Industry Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$305k worth of stock

Full year 2021 earnings released: EPS: HK$0.014 (vs HK$0.02 in FY 2020)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Independent Non-Executive Director recently sold HK$142k worth of stock

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.01 in 1H 2020)

Executive Co-Chairman of the Board recently bought HK$1.7m worth of stock

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Executive Co-Chairman of the Board recently bought HK$441k worth of stock

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group Limited to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day high: HK$0.69

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

New 90-day high: HK$0.57

Executive Co-Chairman of the Board recently bought HK$1.5m worth of stock